Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCC

For patients with hepatocellular carcinoma who have experienced disease progression after receiving standard clinical treatment with lenvatinib in combination with PD-1 inhibitors, the addition of lenalidomide capsules to the three-drug combination therapy was followed by a 2-month follow-up liver imaging examination to observe changes in the target lesion and whether new lesions had developed in other areas.